Literature DB >> 8770701

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.

S Kotake1, K Sato, K J Kim, N Takahashi, N Udagawa, I Nakamura, A Yamaguchi, T Kishimoto, T Suda, S Kashiwazaki.   

Abstract

Chronic immune responses and inflammatory reactions in rheumatoid arthritis (RA) often cause severe destruction of cartilage and bone, but its mechanism is still a matter of controversy. We reported that interleukin-6 (IL-6) alone does not induce osteoclast formation, but soluble interleukin-6 receptors (sIL-6R) triggered the formation in the presence of IL-6 in cocultures of murine osteoblastic cells and bone marrow cells. In this study, we examined the involvement of sIL-6R and IL-6 in joint destruction in patients with RA. Although the frequency of patients having osteoclast-like multinucleated cells in synovium derived from the knee joint was not significantly different between RA (65%) and osteoarthritis (OA) patients (43%), the number of osteoclast-like cells found in the synovium was greater in the former than in the latter. Multinucleated cells obtained from RA synovium expressed the osteoclast-specific phenotype such as tartrate-resistant acid phosphatase, carbonic anhydrase II, vacuolar proton-ATPase and vitronectin receptors at similar levels to those from a human giant cell tumor of bone. The concentration of both IL-6 and sIL-6R was significantly higher in the synovial fluids from patients with RA than with OA. The concentration of IL-6 and sIL-6R correlated well with the roentgenologic grades of joint destruction. Dose-response curves for human IL-6 and human sIL-6R in inducing osteoclast-like cell formation in cocultures indicated that the RA synovial fluids contained sufficient IL-6 and sIL-6R to induce osteoclastogenesis. When synovial fluids from RA and OA patients were added to the cocultures, some of the RA synovial fluids containing high levels of IL-6 and sIL-6R stimulated osteoclast-like cell formation, which was strikingly inhibited by adding anti-IL-6R antibody simultaneously. These results suggest that IL-6 in the RA synovial fluids is at least in part responsible for joint destruction in the presence of sIL-6R through osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770701     DOI: 10.1002/jbmr.5650110113

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  149 in total

1.  Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease.

Authors:  C Schulte; H Goebell; H D Röher; K M Schulte
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

2.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

Authors:  S Kotake; N Udagawa; N Takahashi; K Matsuzaki; K Itoh; S Ishiyama; S Saito; K Inoue; N Kamatani; M T Gillespie; T J Martin; T Suda
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

3.  Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis.

Authors:  E Choy
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 4.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

Review 5.  Osteoclastogenesis and arthritis.

Authors:  Nicola Maruotti; Maria Grano; Silvia Colucci; Francesca d'Onofrio; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2010-11-11       Impact factor: 3.984

6.  Blockade of recombinant human IL-6 by tocilizumab suppresses matrix metalloproteinase-9 production in the C28/I2 immortalized human chondrocyte cell line.

Authors:  Evan C Meszaros; Wissam Dahoud; Sam Mesiano; Charles J Malemud
Journal:  Integr Mol Med       Date:  2015-08-08

7.  Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow.

Authors:  S C Lin; T Yamate; Y Taguchi; V Z Borba; G Girasole; C A O'Brien; T Bellido; E Abe; S C Manolagas
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 8.  Interleukin-6 blockade in ocular inflammatory diseases.

Authors:  M Mesquida; A Leszczynska; V Llorenç; A Adán
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

9.  The Hajdu Cheney mutation sensitizes mice to the osteolytic actions of tumor necrosis factor α.

Authors:  Jungeun Yu; Ernesto Canalis
Journal:  J Biol Chem       Date:  2019-08-01       Impact factor: 5.157

10.  Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.

Authors:  Shumpei Yokota; Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-12       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.